Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

Patients with advanced hepatocellular carcinoma (HCC) have historically had few options and faced extremely poor prognoses if their disease progressed after standard-of-care tyrosine kinase inhibitors (TKIs). Recently, the standard of care for HCC has been transformed as a combination of the immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Greten, Tim F, Abou-Alfa, Ghassan K, Cheng, Ann-Lii, Duffy, Austin G, El-Khoueiry, Anthony B., Finn, Richard S, Galle, Peter R, Goyal, Lipika, He, Aiwu Ruth, Kaseb, Ahmed O, Kelley, Robin Kate, Lencioni, Riccardo, Lujambio, Amaia, Mabry Hrones, Donna, Pinato, David J, Sangro, Bruno, Troisi, Roberto I, Wilson Woods, Andrea, Yau, Thomas, Zhu, Andrew X, Melero, Ignacio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438858/
https://www.ncbi.nlm.nih.gov/pubmed/34518290
http://dx.doi.org/10.1136/jitc-2021-002794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438858/
https://www.ncbi.nlm.nih.gov/pubmed/34518290
http://dx.doi.org/10.1136/jitc-2021-002794

Ejemplares similares